Discontinued drugs in 2007: cardiovascular drugs

This perspective is part of an annual series of papers discussing drugs dropped from clinical development in the previous year. Specifically, this paper focuses on the 16 cardiovascular drugs discontinued in 2007. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I – III clinical trials.     

Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective

This perspective on discontinued cardiovascular drugs is the first in a series of papers on drugs dropped from clinical development in 2006. The compounds described in this perspective have been removed from development in various stages and for different reasons. This paper hereby provides a translational medicine perspective on these compounds based on information available through the Pharmaprojects pipeline database. In particular, potential gaps in the pipeline, due to a lack of biomarkers and translational medicine perspectives are emphasized.     

Discontinued drugs in 2007: oncology drugs

This perspective is part of an annual series of papers discussing drugs dropped from clinical development in the previous year. Specifically, this paper focuses on the 28 oncology drugs discontinued in 2007. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I – III clinical trials.     

Discontinued drugs in 2010: cardiovascular drugs

This perspective is a paper discussing drugs dropped from clinical development in the previous years. Specifically, this paper focuses on 16 cardiovascular drugs discontinued in 2010 after reaching Phase I - III clinical trials. Information for this perspective is mainly derived from a search of Pharmaprojects.     

Discontinued drugs in 2011: cardiovascular drugs

This perspective is part of an annual series of papers discussing drugs dropped from development in the previous year. Specifically, this paper focuses on the 19 cardiovascular drugs discontinued in 2011 after reaching preclinical or Phase I – III clinical trials. Information for this perspective is mainly derived from a search of Pharmaprojects.     

Discontinued drugs in 2008: cardiovascular drugs

This perspective is part of an annual series of papers discussing drugs dropped from clinical development in the previous year. Specifically, this paper focuses on the 16 cardiovascular drugs discontinued in 2008. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I – III clinical trials.     

Discontinued drugs in 2011: cardiovascular drugs

This perspective is part of an annual series of papers discussing drugs dropped from development in the previous year. Specifically, this paper focuses on the 19 cardiovascular drugs discontinued in 2011 after reaching preclinical or Phase I - III clinical trials. Information for this perspective is mainly derived from a search of Pharmaprojects.     

Discontinued drugs, 2007: pulmonary-allergy,dermatological, gastrointestinal and arthritis drugs

This perspective is part of an annual series of papers discussing drugs dropped from clinical development in the previous year. Specifically, this paper focuses on the 17 pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs discontinued in 2007. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I – III clinical trials.     

Discontinued drugs, 2007: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs

This perspective is part of an annual series of papers discussing drugs dropped from clinical development in the previous year. Specifically, this paper focuses on the 17 pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs discontinued in 2007. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I - III clinical trials.     

Discontinued drugs in 2006: oncology drugs

This perspective is the last in a series of papers discussing drugs dropped from clinical development in 2006. Specifically, this paper focuses on the 16 drugs discontinued for the treatment of cancer, the largest area of pharma R&D. This was based on a search of the Pharmaprojects database for drugs reaching Phase I-III clinical trials.     

Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective

This perspective on discontinued cardiovascular drugs is the first in a series of papers on drugs dropped from clinical development in 2006. The compounds described in this perspective have been removed from development in various stages and for different reasons. This paper hereby provides a translational medicine perspective on these compounds based on information available through the Pharmaprojects pipeline database. In particular, potential gaps in the pipeline, due to a lack of biomarkers and translational medicine perspectives are emphasized.     

Discontinued drugs 2011: pulmonary,allergy, gastrointestinal and arthritis

This is the annual perspective paper on the discontinued drugs in the field of pulmonary allergy, gastrointestinal, and arthritis conditions. It is part of series of papers discussing drugs discontinued from clinical development in the previous year and presented according to therapeutic indication. Specifically, this paper presents the 23 compounds developed for various inflammatory conditions and 10 pulmonary drugs which were discontinued in 2011. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase-I – III clinical trials.     

Discontinued drugs 2010: rheumatology,allergy and dermatology,pulmonary

This is the annual perspective paper on the discontinued drugs in the field of pulmonary disease allergy, rheumatology, and dermatology. It is part of series of papers discussing drugs dropped from clinical development in the previous year and presented according to therapeutic indication. Specifically, this paper presents the four rheumatology and dermatology, four pulmonary and three allergy drugs discontinued in 2010. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I – III clinical trials.     

Discontinued drugs 2010: rheumatology, allergy and dermatology, pulmonary

This is the annual perspective paper on the discontinued drugs in the field of pulmonary disease allergy, rheumatology, and dermatology. It is part of series of papers discussing drugs dropped from clinical development in the previous year and presented according to therapeutic indication. Specifically, this paper presents the four rheumatology and dermatology, four pulmonary and three allergy drugs discontinued in 2010. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I - III clinical trials.     

Discontinued drugs 2008: pulmonary and allergy

This is the annual perspectives paper on discontinued drugs in the field of pulmonary disease and allergy. It is part of a series of papers discussing drugs dropped from clinical development in the previous year and presented according to therapeutic indication. Specifically, this paper presents the six pulmonary and five allergy drugs discontinued in 2008. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I – III clinical trials.     

Discontinued drug in 2007: renal, endocrine and metabolic drugs

This perspective is the first part of an annual series of papers discussing drugs dropped from clinical development in the previous year. Specifically, this paper focuses on the 14 renal, endocrine and metabolic drugs discontinued in 2007. The candidates covered in this summary were being developed for treatment of diabetes, obesity, reproductive and urogenital health issues, and growth hormone deficiency. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I - III clinical trials.     

Discontinued drug in 2007: renal,endocrine and metabolic drugs

This perspective is the first part of an annual series of papers discussing drugs dropped from clinical development in the previous year. Specifically, this paper focuses on the 14 renal, endocrine and metabolic drugs discontinued in 2007. The candidates covered in this summary were being developed for treatment of diabetes, obesity, reproductive and urogenital health issues, and growth hormone deficiency. Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I – III clinical trials.     

Discontinued drugs in 2010: oncology drugs

The Pharmaceutical Industry is currently undergoing a period of rapid change as the pressures of the financial markets highlight fundamental inefficiencies in the current business model. The Achilles heel for the industry is the unacceptable level of attrition in clinical drug development. An imperative for the industry is to reduce the cost and increase the efficiency of Research and Development (R&D). This article provides an analysis of cancer drugs dropped from the industry pipeline in 2010 and offers a perspective on how the future oncology drug pipeline might evolve.     

Discontinued drugs in 2005: cardiovascular drugs

This perspective describes cardiovascular compounds dropped from clinical development in 2005 and is the first in a series of papers to be published in Expert Opinion on Investigational Drugs, discussing discontinued drugs from that year. Discontinued candidates are described by the phase of development they reached, based on the information available from the Pharmaprojects database. Discontinued drugs in the atherosclerosis/dyslipidaemia area are discussed in more detail.     

Discontinued drugs in 2005: cardiovascular drugs

This perspective describes cardiovascular compounds dropped from clinical development in 2005 and is the first in a series of papers to be published in Expert Opinion on Investigational Drugs, discussing discontinued drugs from that year. Discontinued candidates are described by the phase of development they reached, based on the information available from the Pharmaprojects database. Discontinued drugs in the atherosclerosis/dyslipidaemia area are discussed in more detail.